Welcome to our dedicated page for Catalent news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on Catalent stock.
Catalent, Inc. (historically NYSE: CTLT) generates frequent news as a global contract development and manufacturing organization (CDMO) serving pharma, biotech, and consumer health customers. Company announcements emphasize its mission to develop, manufacture, and supply products that help people live better and healthier lives, as well as its role in optimizing product development, launch, and full life-cycle supply.
News about Catalent often covers its corporate transactions and ownership structure. A major recent theme has been the acquisition of Catalent by Novo Holdings A/S, a global life sciences investment firm. Press releases detail the signing of the merger agreement, regulatory approvals, fulfillment of closing conditions, and the completion of the all-cash transaction, after which Catalent became a private company and its common stock ceased trading on the New York Stock Exchange.
Operational updates are another key news category. Catalent has reported expansions of its global network, such as the completion of a significant expansion at its Schorndorf, Germany clinical supply facility, adding temperature-controlled storage, a new automatic bottle filling line, and dedicated space for its FastChain demand-led supply service. The company has also announced portfolio changes, including an agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, New Jersey, which also houses its corporate headquarters during a transition period.
Financial results and segment performance feature prominently in Catalent’s news flow. The company publishes quarterly and annual results, including net revenue, segment performance for Biologics and Pharma and Consumer Health, and non-GAAP metrics such as Adjusted EBITDA and Adjusted Net Income, along with commentary on trends in non-COVID revenue and leverage ratios.
Governance and leadership developments also appear in Catalent’s news, such as new Board appointments and updates to its Board composition under Novo Holdings’ ownership. For readers tracking CTLT-related developments, this news stream provides context on Catalent’s evolution from a public CDMO to a privately held company, its investment in global capacity, and its ongoing role in supporting the development and supply of treatments worldwide.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Catalent, Inc. (NYSE: CTLT) announced a business update reflecting challenges during the third fiscal quarter ending March 31, 2023. The company expects higher costs and productivity issues at three facilities, impacting financial results. Specifically, the Harmans, Maryland facility faced operational setbacks related to a new ERP system deployment, affecting revenue generation. Similar issues were reported at facilities in Bloomington, Indiana and Brussels, Belgium, which may persist into the next quarter. In leadership changes, Ricky Hopson is appointed Interim Chief Financial Officer as of April 14, 2023. The company anticipates releasing Q3 fiscal year results on May 9, 2023, which may clarify the financial impact of these challenges.
Catalent, Inc. (NYSE: CTLT) has announced participation in two major investor conferences in March 2023. The first event is the Barclays Global Healthcare Conference on March 14 at 10:45 a.m. ET, followed by the KeyBanc Life Sciences & MedTech Investor Forum on March 21 at 12:00 p.m. ET. Interested investors can access a live webcast of both presentations through the Catalent investor relations page. Catalent, headquartered in Somerset, New Jersey, generated nearly $5 billion in revenue for the 2022 fiscal year and is a leader in the development and supply of pharmaceutical and biotech treatments.
FAQ
What is the current stock price of Catalent (CTLT)?
What is the market cap of Catalent (CTLT)?
